Walder Wyss advises +ND Capital on its exit from CellPoint by sale to Galapagos
+ND Capital has exited Dutch cell therapy company CellPoint by sale to the Belgian biotech company Galapagos which has acquired CellPoint for $131 million upfront and up to $105 million in milestone payments.
As sole venture investor in CellPoint, a company dedicated to developing CAR-T therapies at the point-of-care, the sale underlines +ND Capital’s success in Europe, being its second exit after Arctos Medical sale to Novartis.
Headquartered in California, +ND Capital is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences. Currently they have over $500M under management and are currently investing our $335M third fund.
Walder Wyss has advised +ND Capital through its entire investment and in the sale transaction. The legal team was led by partner Luc Defferrard (corporate/m&a, pictured) and included Michael Kündig (senior associate, corporate/m&a) and Alice Vorburger (associate, corporate/m&a).
